TIDMABC

RNS Number : 4392Y

ABCAM Plc

01 December 2014

 
 For immediate release   1 December 2014

ABCAM PLC

("Abcam" or "the Company")

Total Voting Rights - Voting Rights and Capital

In conformity with 5.6.1 of the Disclosure and Transparency Rules, the Company notifies the market of the following:

The Company's issued share capital consists of 200,865,479 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.

The above figure of 200,865,479 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

Date of Notification: 1 December 2014

For further information please contact:

 
 Abcam                                     + 44 (0) 1223 696 000 
 Alan Hirzel / Jeff Iliffe 
 Numis Securities - Nominated Adviser 
  and Joint Broker                         + 44 (0) 20 7260 1000 
 Michael Meade - Nominated Adviser 
 James Black - Corporate Broking 
 Peel Hunt LLP - Joint Broker              + 44 (0) 20 7418 8900 
 Clare Terlouw / Jock Maxwell MacDonald 
  - Corporate Broking 
 Brunswick                                 + 44 (0) 20 7404 5959 
 Justine Mcllroy / Robin Wrench / Emma 
  Walsh

Notes for editors:

About Abcam plc

Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices enabling local services, multi-language support sells to over 100 countries. The Company was founded in 1998, and now employs over 740 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRUGGGUPUPCUBG

Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abcam Charts.
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abcam Charts.